Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

We have previously reported on the efficacy and tolerability of hyper-CVAD regimen (cyclophosphamide, vincristine, Adriamycin, and dexamethasone) and imatinib followed by imatinib-based consolidation/maintenance therapy in 20 patients with newly diagnosed Philadelphia-positive acute lymphoblastic le...

Full description

Bibliographic Details
Main Authors: Naval Daver, Deborah Thomas, Farhad Ravandi, Jorge Cortes, Rebecca Garris, Elias Jabbour, Guillermo Garcia-Manero, Gautam Borthakur, Tapan Kadia, Michael Rytting, Marina Konopleva, Hagop Kantarjian, Susan O’Brien
Format: Article
Language:English
Published: Ferrata Storti Foundation 2015-05-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/7373

Internet

https://haematologica.org/article/view/7373

Similar Items